Cardiac Dimensions, Inc. is currently enrolling for a study of the CARILLON®
Mitral Contour System™. Patients being considered for the study are on optimal
heart failure medication treatment, but who still have moderate to severe
functional mitral valve regurgitation and impaired heart function. Treated
patients will be followed at 1, 3, 6 and 12 months post procedure.
The
TITAN II study is a multi-center safety study being conducted at sites located
in Europe. United States residents are not eligible for the TITAN II study.